EcoDrugPlus

Group 10 Secretory Phospholipase A2-Like

Ensembl ID : ENSNFUG00015000336
Gene Symbol: LOC107378410
3 Cross references
232 Possible Orthologues:

Growth Hormone Secretagogue Receptor A

Ensembl ID : ENSNFUG00015023050
Gene Symbol: GHSRA
1 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSNFUG00015007767
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSNFUG00015002520
Gene Symbol: GUCY1A2
1 Cross references
187 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSNFUG00015002517
Gene Symbol: GUCY1A2
1 Cross references
176 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSNFUG00015007645
Gene Symbol: GUCY1B1
1 Cross references
210 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSNFUG00015000474
Gene Symbol: HSP90AB1
3 Cross references
339 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 1

Ensembl ID : ENSNFUG00015011193
Gene Symbol: HSP90AA1.1
1 Cross references
330 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha

Ensembl ID : ENSNFUG00015011529
Gene Symbol: LOC107378075
3 Cross references
345 Possible Orthologues:

High Mobility Group Box 1

Ensembl ID : ENSNFUG00015013607
Gene Symbol: HMGB1
3 Cross references
511 Possible Orthologues:

High Mobility Group Protein B1-Like

Ensembl ID : ENSNFUG00015002796
Gene Symbol: LOC107380026
3 Cross references
509 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSNFUG00015005075
Gene Symbol: HRH1
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).